In this study, we found a DNA methylation signature involving MYF6, RPTOR, MMP10, SH3PXD2B, VHL and GABBR1, which could be a valuable tool in guiding treatment decisions for AML. This evidence concerns the gene GABBR1 and acute myeloid leukemia.